second-line
Park H, Klempner SJ, Chao J, Wainberg ZA, Lukanowski M, Chenji S, Bourke S, Chatterjee A, Lorenzen S. Ramucirumab plus FOLFIRI or irinotecan as second-line[...]
Department of Medicine
A community resource for faculty and staff